Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (431-440 of 478) with videos related to

Pageof 48
Sort By:
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Frontiers in Immunology|March 1, 2024
Immunometabolic features of natural killer cells are associated with infection outcomes in critical illnessKuei-Pin Chung, Jia-Ying Su, Yi-Fu Wang, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
Nature Communications|April 13, 2021
Epigenetic modulation of immune synaptic-cytoskeletal networks potentiates γδ T cell-mediated cytotoxicity in lung cancerRueyhung R Weng, Hsuan-Hsuan Lu, Chien-Ting Lin, et al.
Nature Communications|August 22, 2024
Alveolar epithelial cells mitigate neutrophilic inflammation in lung injury through regulating mitochondrial fatty acid oxidationKuei-Pin Chung, Chih-Ning Cheng, Yi-Jung Chen, et al.
Lancet (London, England)|January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyJean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Pageof 48

Showing results (431-440 of 478) with videos related to

Sort By:
Pageof 48
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Frontiers in Immunology|March 1, 2024
Immunometabolic features of natural killer cells are associated with infection outcomes in critical illnessKuei-Pin Chung, Jia-Ying Su, Yi-Fu Wang, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
Nature Communications|April 13, 2021
Epigenetic modulation of immune synaptic-cytoskeletal networks potentiates γδ T cell-mediated cytotoxicity in lung cancerRueyhung R Weng, Hsuan-Hsuan Lu, Chien-Ting Lin, et al.
Nature Communications|August 22, 2024
Alveolar epithelial cells mitigate neutrophilic inflammation in lung injury through regulating mitochondrial fatty acid oxidationKuei-Pin Chung, Chih-Ning Cheng, Yi-Jung Chen, et al.
Lancet (London, England)|January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyJean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Pageof 48